Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Francis Collins and James Greenwood were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Collins and Greenwood featured in the government and policy section, as LSIPR reports.   5 October 2016
Americas
Jarbas Barbosa da Silva Jr and Margaret Chan were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports.   5 October 2016
Biotechnology
James Love was selected in the LSIPR 50 2016 publication for his influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports.   5 October 2016
Asia
Xi Jinping and George Freeman were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Jinping and Freeman were featured in the government and policy section, as LSIPR reports.   5 October 2016
Americas
Enzo Life Sciences, a distributor of life sciences products, has filed a complaint against diagnostics supplier Hologic for allegedly infringing a patent centring on several technologies.   5 October 2016
Asia
Myanmar authorities have seized K2.8 billion worth of counterfeit and expired drugs.   5 October 2016
Americas
US pharmaceutical company Depomed has won a patent case in the US District Court for the District of New Jersey against three filers of Abbreviated New Drug Applications covering Nucynta.   4 October 2016
Americas
Allergan and MedImmune have entered into a $1.52 billion licensing agreement under which Allergan has gained the global rights to develop MEDI2070, which treats inflammatory disorders.   4 October 2016
Americas
The $3.6 billion acquisition of the Thomson Reuters Intellectual Property & Science business by Onex Corporation and Baring Equity Asia was completed yesterday.   4 October 2016
Americas
Biopharmaceutical company Amgen and drug manufacturer Arrowhead Pharmaceuticals have entered into two agreements to develop and commercialise RNA interference therapies for cardiovascular disease.   3 October 2016